Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Kraft

Neurology Chattanooga, TN Medical Doctor

NPI 1326097262 CMS profile 599968

721 Glenwood Dr, Ste 467, Chattanooga, TN 37404

Open in the dashboard

General payments

$17,475

1,007 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Kraft of Chattanooga, TN is reported in the CMS Open Payments database as having received $17,475 across 1,007 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,160 143
2024 General $3,128 176
2023 General $2,903 177
2022 General $2,573 153
2021 General $2,814 186
2020 General $1,368 80
2019 General $1,530 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Kraft
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Howard Kraft were reported at $3,160. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Howard Kraft Neurology median Middle half National median
2019 $1,530 $474 $118–$2,177 $163
2020 $1,368 $367 $82–$2,309 $114
2021 $2,814 $438 $104–$2,547 $132
2022 $2,573 $442 $103–$2,388 $149
2023 $2,903 $464 $119–$2,312 $160
2024 $3,128 $468 $119–$2,323 $164
2025 $3,160 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,948 229 payments
  2. UCB, Inc. $1,429 58 payments
  3. Allergan Inc. $897 63 payments
  4. Pfizer Inc. $857 51 payments
  5. Novartis Pharmaceuticals Corporation $796 40 payments
  6. Amgen Inc. $653 29 payments
  7. Biogen, Inc. $652 42 payments
  8. Biohaven Pharmaceuticals, Inc. $596 42 payments
  9. Celgene Corporation $585 45 payments
  10. ACADIA Pharmaceuticals Inc $567 33 payments
  11. Other $7,496 375 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,330 1,001 payments
  2. Education $85 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $60 3 payments
Products named General payments · program years 2019–2025
  1. Briviact $1,212 47 payments
  2. UBRELVY $1,017 105 payments
  3. BOTOX Botox Therapeutic $857 53 payments
  4. BOTOX Hyperhydrosis $853 55 payments
  5. NURTEC ODT Primary Care $812 56 payments
  6. QULIPTA $752 60 payments
  7. AIMOVIG $630 29 payments
  8. ZEPOSIA $589 45 payments
  9. NURTEC ODT Pain $546 37 payments
  10. INGREZZA $483 25 payments
  11. Other $11,240 595 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 92 drugs

Part D claims

5,538

Median for Neurology: 833

Drug cost

$3,043,062

Median for Neurology: $202,670

Branded share of claims

27.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 38 $674,680
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 36 $464,632
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 13 $460,002
Kesimpta Pen Ofatumumab Brand 42 $346,854
Avonex Pen (4 Pack) Interferon Beta-1a Brand 18 $194,109
Nuplazid Pimavanserin Tartrate Brand 24 $169,691
Qulipta Atogepant Brand 73 $99,633
Nurtec Odt Rimegepant Sulfate Brand 66 $96,040
Austedo Deutetrabenazine Brand 19 $89,149
Copaxone Glatiramer Acetate Brand 12 $69,283

The 10 drugs with the highest cost, of 92 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$1,317,688

Of which drugs: $1,192,485

Medicare patients

662

Average age 74

Services billed

44,683

383 women, 279 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Depression 34%
Ischemic heart disease 33%
Diabetes 31%
Chronic kidney disease 27%
Osteoporosis 19%
Alzheimer's or dementia 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 26 11,420 $51,907

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 38 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Briviact
$453 25 —
BOTOX
$264 — 11,420
INGREZZA
$228 — —
KESIMPTA
$161 42 —
ULTOMIRIS
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 38 with Patron

Records

1,007 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record